Fig 5
A look at the long-term effectiveness of an integrated tinnitus management approach (WZT) and the pattern of therapy use among primary tinnitus patients once successful remediation of symptoms is achieved.
The UK-based charity, Action on Hearing Loss, announced that it is funding a tinnitus study at Newcastle University to help accelerate the development of future tinnitus treatments.
Serenity Tinnitus Therapy Diagram
Sanuthera announced that it has submitted its Serenity tinnitus device to the FDA for 510(k) clearance.
Quell device
Amplisound has announced the release of a new tinnitus device called Quell, which is designed to be used effectively with any tinnitus therapy. While there are many devices available for tinnitus relief, including hearing aids, Quell is particularly suitable for patients who respond specifically to sound therapy and do not want a hearing aid or need amplification.
Figure 4. Individual subject Tinnitus Functional Index (TFI) baseline and 6 months post Widex Zen Therapy scores for the 24 subjects. The solid line represents equivalent baseline vs final (post treatment) scores while the dashed line represents the 13-point benefit score required for clinical efforts to be considered clinically significant.
The results from this clinical study strongly support the use of Widex Zen Therapy in tinnitus patient management. This individualized comprehensive approach combining counseling (instructional and adjustment-based cognitive behavioral intervention), amplification, fractal tones and/or noise, and relaxation strategies was highly effective in reducing tinnitus handicap in a short period of time, with improvements apparent through at least the 6-month duration of this investigation.
The Tinnitus Practitioners Association (TPA) has announced its 3rd Annual International Misophonia Conference, which will be held in Phoenix, Ariz, on February 20-21, 2015.
The AAO-HNS guideline gives healthcare providers a framework for care and support in mitigating the personal and social impact that tinnitus can have. The recommendation includes obtaining a comprehensive audiologic examination and recommendation of sound therapy for patients with persistent bothersome tinnitus.
Audiology Systems and Otometrics is launching a series of new reference materials and training to assist audiologists and other hearing care professionals interested in adding tinnitus treatment to their practice.
The MADSEN Astera2 features a dedicated tinnitus assessment module designed to help clinicians address increased claims for tinnitus and hearing loss disability.
The Hearing Review asks three audiologists associated with GN Otometrics and Audiology Systems—Clément Sanchez, AuD, Wendy Switalski, AuD, and Clint Keifer, AuD—for their thoughts on the benefits of tinnitus assessment. They also provide advice to hearing care professionals who are interested in adding tinnitus assessment to their practice.
ear ringing
A look at what the most recent scientific literature says about tinnitus treatment, as well as a review of Cognitive Behavioral Therapy (CBT), Progressive Tinnitus Management (PTM), and Tinnitus Retraining Therapy (TRT).
The results of a randomized, multi-center clinical study published in AJA by Richard Tyler, PhD, and colleagues found SoundCure’s S-Tones® to be effective at quiet volumes and to be more effective than broadband noise in the reduction of tinnitus.
The Levo System reportedly leverages the brain's natural cognitive abilities,  and identifies and maps an individual's unique sound print using custom-fit ear buds and proprietary software on Apple iPad® and iPod® touch mobile digital devices.
The Levo System from Otoharmonics reportedly leverages the brain's natural cognitive abilities, and identifies and maps an individual's unique sound print using custom-fit ear buds and proprietary software on Apple iPad® and iPod® touch mobile digital devices.
The first clinical trial to investigate the effect of a standardized physical therapy treatment, directed to the cervical spine, on tinnitus is being conducted at the University of Antwerp.
logo auris_medical_2f
Auris Medical Holding AG —the developer of treatments for acute inner ear tinnitus (AM-101) and acute inner ear hearing loss (AM-111) by way of intratympanic injection—announced on August 6 pricing of its IPO. The company's common shares have been approved for listing on the NASDAQ Global Market and are expected to begin trading under the ticker symbol “EARS”.
Loyola University surgeon says athletes who play football and other contact sports may be at risk for hearing damage and tinnitus.

Data Watch

Powered By:
Patients with tinnitus process emotions differently in the brain from those with normal hearing, researchers report in the journal Brain Research.
Neuromonics Sanctuary opt
Neuromonics, a manufacturer and distributor of tinnitus treatment devices, has signed a reseller agreement with AuDConnex.
UWA tinnitus
Researchers at The University of Western Australia have shown changes in a part of the brain previously not known to be involved in tinnitus generation.
The left figure shows an inner hair cell, with its hair bundle at one end and with 3 of its roughly 20 synapses with cochlear nerve terminals at the other end. The cell's nucleus is shown in red, and each synapse is marked by a smaller red dot. Immunostain recognizes a molecule present in the nucleus and also in a key synaptic component within the hair cell, called a “ribbon.” The images shown on the right were taken with a confocal microscope. The upper image shows 8 inner hair cells from a normal ear (each cell has one large red nucleus) and about 150 small red dots (arrowheads), each of which shows a synapse between a hair cell and a cochlear nerve fiber. The bottom image shows another ear a few days after exposure to a noise that caused only a transient threshold elevation. The confocal image shows no loss of hair cells, but a striking loss of synapses, which will never recover.
The new findings suggest that noise-induced hearing loss has another very important component beyond just hair cells: the loss of cochlear nerve fibers.
In Part 4 of this 5-part series, our roundtable takes on the topics of marketing and outreach to physicians, changing attitudes about hearing aids in younger patients, and a greater willingness to try new technology.